Exclusive: Clearmind And SciSparc To Conduct Study Evaluating Psychedelics And CannAmide Based Drug For Treatment Of Obesity And Metabolic Syndrome
Clearmind Medicine Inc. (NASDAQ: CMND) (CSE:CMND) (FSE:CWY) announced that as part of the company's ongoing collaboration with SciSparc Ltd.